ClinicalTrials.gg
RecruitingNCT06860165EMC2FRUpdated Jul 22, 2025

Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression

An observational study in Unipolar Depression, Major Depressive Disorder (MDD) and Depression, sponsored by Emobot. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Primary conditionDepressive Disorder, MajorRegistry: Depressive DisorderReclassifiedWhy we changed it
Registry
Depressive Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depressive Disorder, Major
Why
  1. The study's listed conditions name Depressive Disorder, Major, a narrower term within Depressive Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Emobot · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
98
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Depressive Disorder, Major with a site in France — 28 open to participants now, 31 under way, 2 of them phase 3. Depressive Disorder, Major · France.

Planned enrollment
13th of 21
98 · median 128
Started
2025
with 9 others
Observational
21 of 127
7 open now
Primary completion
2025-12
later than 5 of 30 live
Registered
118th of 127
by date

Among the 127 studies in Depressive Disorder, Major with a site in France, this one is the 13th largest by planned enrollment of the 21 observational ones that give a count, is one of 10 that started in 2025, is one of 21 observational ones, reaches primary completion later than 5 of the 30 other live ones, and was the 118th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

28 of the 127 studies in Depressive Disorder, Major with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Depressive Disorder, Major with a site in France, or all of them as a file.
02

Study summary

The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach. The device studied, EmoDTx, is a mood-monitoring application that analyzes patients' facial expressions to assess their emotional state. The study aims to compare mood scores obtained via EmoDTx with those of standard depression questionnaires (MADRS, PHQ-9, BDI-II, HAMD-17, QIDS-SR16). It will also provide information on how patients feel about the use of passive monitoring software (without the active involvement of the patient) and how the feedback sent to patients can help in their care.

Participants who agree to take part in the study, during a selection visit, will be able to:

  1. Install the software on a digital interface (smartphone, computer, etc.) and activate or deactivate it whenever they wish during the 8-week follow-up period.
  2. Attend scheduled appointments at the center (a first appointment, then a second 4 weeks later, and a final at 8 weeks) to complete a series of questionnaires, be questioned by the doctor, and fill in other questionnaires on their own.
  3. At home, answer questionnaires independently, 2 weeks and 6 weeks after the first appointment.
  4. The application's feedback will be deactivated during the first 4 weeks and then reactivated during the final 4 weeks.
  5. In parallel, an ancillary study will be conducted on 16 patients enrolled in EMC2FR who accepted and performed the video recording of their structured clinical interview following SCID-5-CV at baseline and 4 weeks.
03

Conditions studied

  • Unipolar Depression
  • Major Depressive Disorder (MDD)
  • Depression

Browse trials for

04

In context

Depressive Disorder, Major Reclassified

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

This study's planned enrollment of 98 is below the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

Emobot is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Compared within Depressive Disorder, Major, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients suffering from mild to severe unipolar depression

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatients diagnosed with mild to severe unipolar disorder
  2. Age ≥ 18 years old
  3. Patients willing and able to participate (i.e willing to use the EmoDTx App and having the necessary technical equipment to use it)
  4. Patients who read, write and understand French
  5. Patients having signed the Patient

Exclusion criteria

Exclusion criteria:

  1. Patients hospitalized
  2. Patients taking more than 75% of the maximal recommended daily dose of benzodiazepines
  3. Patients taking more than 75% of the maximal recommended daily dose of antipsychotics
  4. Patients taking more than 75% of the maximal recommended daily dose of neuroleptics
  5. Patients who did not respond to 10 different pharmacological treatments
  6. Patients who attempted suicide within the previous last 6 months and presenting with suicidal ideations
  7. Patient presenting with bipolar disorders
  8. Patients with a to the device under evaluation:

    • Severe depression requiring hospitalization
    • Schizophrenic disorders according to DSM 5 classification
    • Major neurocognitive disorders according to DSM 5 classification
    • Illiteracy
    • Subject hospitalized in a healthcare or social institution for reasons other than biomedical research or is deprived of freedom by administrative or judicial decision or is placed under guardianship
  9. Patients unable to read, write and understand French
  10. Patients with no access to a smartphone or a computer with an internet connection
  11. Patients who refuse to sign the Patient
  12. Patients already participating in another interventional clinical study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
98 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. Change of score EmoDTx

    Absolute difference

    Time frame: From baseline to 4 weeks

  2. Change of score MADRS administrated by an investigator

    Absolute difference

    Time frame: From baseline to 4 weeks

Secondary outcomes

  1. Change of EmoDTx score

    Time frame: Between 2 weeks and 6 weeks

  2. Change of score PHQ-9 self reported

    Time frame: Between 2 weeks and 6 weeks

  3. Change of EmoDTx score

    Time frame: Between Baseline and 4 weeks, between Baseline and 8 weeks and between 4 weeks and 8 weeks

  4. Change of HAMD-17 questionnaire administered by the investigator

    Time frame: Between Baseline and 4 weeks, between Baseline and 8 weeks and between 4 weeks and 8 weeks

  5. Change of EmoDTx score

    Time frame: between Baseline and 4 weeks - between Baseline and 8 weeks - between 4 weeks and 8 weeks

  6. Change of score QIDS- SR16 self administrated

    Time frame: between Baseline and 4 weeks - between Baseline and 8 weeks - between 4 weeks and 8 weeks

  7. Change of score BDI-II self administrated

    Time frame: between Baseline and 4 weeks - between Baseline and 8 weeks - between 4 weeks and 8 weeks

  8. Score EmoDTx

    Time frame: At 4-weeks, at 8 week

  9. Score MADRS administrated by the investigator

    Time frame: At 4-weeks, at 8 week

  10. Score HAMD-17 administrated by the investigator

    Time frame: At 4-weeks, at 8 week

  11. Score PHQ-9 self administrated

    Time frame: At 2-weeks and 6 weeks.

  12. Score QIDS-SR16 self administrated

    Time frame: At 4-weeks and 8 weeks

  13. To evaluate the ability of EmoDTx to predict changes in patient's mood earlier than the standard-of-care questionnaires HAMD-17, within 4 weeks and 8 weeks of follow-up.

    Time frame: Time to detection by EmoDTx of changes to depression severity symptoms within 4 weeks and 8 weeks of follow-up as compared to changes detected by standard-of-care questionnaires HAMD-17 Changes in depression severity

  14. To evaluate the ability of EmoDTx to predict changes in patient's mood earlier than the standard-of-care questionnaires MADRS, within 4 weeks and 8 weeks of follow-up.

    Time frame: Time to detection by EmoDTx of changes to depression severity symptoms within 4 weeks and 8 weeks of follow-up as compared to changes detected by standard-of-care questionnaires MADRS Changes in depression severity

  15. Score EQ-5D-5L

    Time frame: At 4 weeks and 8 weeks

  16. Change of EmoDTx score when feedback is deactivated

    Time frame: From baseline to 4 weeks

  17. Change of EmoDTx score when feedback is activated

    Time frame: From 4 weeks to 8 weeks

  18. Acceptability of medical device questionnaire

    Time frame: A baseline and 8 weeks

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2025, 4 months after the start.

Of 29 industry-sponsored observational studies under Depressive Disorder, Major, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 33. This study's planned 4 months is below that.

Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Mar 5, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Dec 9, 2025
CompletionEst.
Dec 9, 2025
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06860165
Lead sponsor
Emobot
Collaborators
Nîmes University Hospital
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Jul 15, 2025
Primary completion
Dec 9, 2025 (estimated)
Completion
Dec 9, 2025 (estimated)
Last update
Jul 22, 2025

Study contacts

Tanel PETELOT
Contact
contact@emobot.fr
+33 6 51 44 26 67

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion